Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378798 | 1.00 | AR (0.41) | ARPGRSLC22A12CUL4APDK2 | |
| SCHEMBL25983090 | 0.87 | AR (0.46) | ARPGRSLC22A12PDK2TSHR | |
| SCHEMBL17030741 | 0.82 | TSHR (0.39) | ARPGRSLC22A12CUL4APDK2 | |
| SCHEMBL2047143 | 0.79 | HCAR1 (0.35) | — | |
| SCHEMBL20455609 | 0.79 | TRPA1 (0.33) | — | |
| SCHEMBL29890653 | 0.79 | TRPA1 (0.33) | — | |
| SCHEMBL3911267 | 0.79 | AR (0.46) | ARPGRSLC22A12 | |
| SCHEMBL2658869 | 0.78 | AR (0.40) | ARPGRPDK2TSHR | |
| SCHEMBL5228912 | 0.78 | TSHR (0.54) | ARPGRTSHR | |
| SCHEMBL16960191 | 0.78 | AR (0.40) | ARPGRPDK2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4121044-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4013750-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022063437-A1 | COMPOSITIONS FOR THE TREATMENT OF SALIVARY GLAND CARCINOMA | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| CN-113698315-A | Synthetic method of 2-trifluoromethyl benzamide | 内蒙古蓝科生物科技有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-7608604-B2 | Antiparasitic agents | PFIZER LIMITED (GB) | 2009-10-27 | — | — | US | disclosed |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | PFIZER LIMITED (UK) | 2008-08-14 | — | — | US | disclosed |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| CN-1997630-A | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| EP-1773772-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006024931-A2 | THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | HRH4, HRH3, HRH2 | AR 4573/4885PGR 3544/4885SLC22A12 1098/4885 |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | AR 2395/4885PGR 568/4885SLC22A12 3398/4885 |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | AR 2395/4885PGR 568/4885SLC22A12 3398/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | AR 1946/4885PGR 1083/4885SLC22A12 2622/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | AR 2395/4885PGR 568/4885SLC22A12 3398/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | AR 1452/4885PGR 747/4885SLC22A12 910/4885 |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | TNNC1, TNNI3, TNNT2 | AR 500/4885PGR 1921/4885SLC22A12 3942/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | AR 2395/4885PGR 568/4885SLC22A12 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.